Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to investigate the efficacy and safety of long-term administration of the oral proteasome inhibitor ixazomib as part of ixazomib in combination with lenalidomide and dexamethasone (IRd) therapy in patients with relapsed and/or refractory multiple myeloma (RRMM) treated initially with an injectable proteasome inhibitor-based therapy.


Clinical Trial Description

The drug being tested in this study is called Ixazomib. Ixazomib is being tested to treat people who have RRMM. This study will look at the effectiveness and safety of IRd in participants with RRMM previously receiving an injectable proteasome inhibitor-based therapy. This study consists of two treatment periods, Treatment Period I and Treatment Period II. The study will enroll 47 patients. All participants will receive following treatment: - Combination therapy with Bortezomib + Lenalidomide + Dexamethasone (VRd) or combination therapy with Carfilzomib + Lenalidomide + Dexamethasone (KRd), standard recommended dose according to the package insert of each drug, as Treatment Period I, followed by Combination therapy with Ixazomib 4.0 mg + Lenalidomide 25 mg + Dexamethasone 40 mg (IRd) as Treatment Period II At start of this study, combination therapy of VRd or KRd will be decided by investigator as Treatment Period I after the baseline evaluations. After the start of Treatment Period I, a participant's eligibility for Treatment Period II is then determined 3 cycles. Participants who meet these eligibility criteria II subsequently continue into Treatment Period II and receive IRd. This multi-center trial will be conducted in Japan. It is anticipated that the treatment phase of this study will last up to 39 months, including 18 months for enrollment. Participants will make multiple visits to the clinic in treatment period, and follow-up period including a follow-up assessment after last dose of study drug. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03416374
Study type Interventional
Source Takeda
Contact
Status Completed
Phase Phase 4
Start date February 18, 2018
Completion date May 28, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT03140943 - Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Phase 2
Recruiting NCT05066022 - A Study to Access the Safety and Efficacy of CT0590 in Patients With Relapsed and/or Refractory Multiple Myeloma N/A
Recruiting NCT06182696 - OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM Phase 1/Phase 2
Recruiting NCT03715478 - Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex Phase 1/Phase 2
Completed NCT02917941 - A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Refractory Multiple Myeloma Phase 2
Not yet recruiting NCT03903406 - Quality of Life, Symptoms and Treatment Satisfaction in Adult Patients With Relapsed and/or Refractory Multiple Myeloma, Receiving Ixazomib (Ninlaro®) in Combination With Lenalidomide and Dexamethasone in a Real World Setting: Pilot Study
Completed NCT03242460 - The Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Transplant-ineligible Patients With Relapsed and/or Refractory Multiple Myeloma (MM) Phase 2
Terminated NCT03836053 - Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma Phase 1
Recruiting NCT05719701 - Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma Phase 1/Phase 2
Recruiting NCT05297240 - Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain.
Terminated NCT04272775 - A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) Phase 1
Not yet recruiting NCT06351644 - ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Phase 1/Phase 2
Withdrawn NCT04392648 - A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) Phase 1
Active, not recruiting NCT01632150 - Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma Phase 2
Completed NCT02831686 - A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma Phase 1
Recruiting NCT06153251 - A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma Phase 1
Completed NCT00882063 - Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Refractory Multiple Myeloma Phase 1/Phase 2
Terminated NCT04017130 - A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma Phase 1
Recruiting NCT05486975 - This is an Open-label, Single Arm Study to Evaluate the Safety and Tolerability of Treatment With CT0591CP in Patients With Relapsed and/or Refractory Multiple Myeloma. Early Phase 1
Completed NCT03170882 - A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma Phase 2